sodium nitrite inhalation (AIR001) / Savara - LARVOL DELTA

Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis (clinicaltrials.gov) - P1/2 | N=4 | Terminated | Sponsor: Schmidhofer, Mark, MD | N=35 ➔ 4 | Active, not recruiting ➔ Terminated; Protocol closed due to difficulty recruiting subjects and then expiration of investigational product and lack of a manufacturer.

Enrollment change • Trial termination • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis (clinicaltrials.gov) - P1/2 | N=35 | Active, not recruiting | Sponsor: Schmidhofer, Mark, MD | Trial completion date: Apr 2022 ➔ Apr 2023 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis (clinicaltrials.gov) - P1/2; N=35; Active, not recruiting; Sponsor: Schmidhofer, Mark, MD; Trial completion date: Apr 2021 ➔ Apr 2022; Trial primary completion date: Dec 2020 ➔ Dec 2021

Trial completion date • Trial primary completion date • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases

Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis (clinicaltrials.gov) - P1/2; N=35; Active, not recruiting; Sponsor: Schmidhofer, Mark, MD; Recruiting ➔ Active, not recruiting; Trial completion date: Apr 2020 ➔ Apr 2021; Trial primary completion date: Apr 2020 ➔ Dec 2020

Enrollment closed • Trial completion date • Trial primary completion date